Related Experiment Video

Updated: Apr 11, 2026

An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy
07:45

An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy

Published on: October 21, 2014

8.5K

Emerging treatments for pediatric leukodystrophies

Guy Helman1, Keith Van Haren2, Maria L Escolar3

  • 1Department of Neurology, Children's National Health System, 111 Michigan Avenue, Northwest, Washington, DC 20010, USA; Center for Genetic Medicine Research, Children's National Health System, 111 Michigan Avenue, Northwest, Washington, DC 20010, USA.

Pediatric Clinics of North America
|May 30, 2015
PubMed

Insights

Leukodystrophies are inherited brain disorders. Advances in diagnostics are enabling targeted therapies, moving beyond symptom management to potentially reduce unmet needs for patients.

Area of Science:

  • Neuroscience
  • Genetics
  • Rare Diseases

Background:

  • Leukodystrophies encompass diverse inherited neurological disorders.
  • These conditions present with varied clinical symptoms and pathological mechanisms.
  • Historically, understanding and treating these diseases has been challenging.

Purpose of the Study:

  • To highlight the impact of improved diagnostic methods on understanding leukodystrophies.
  • To discuss the shift towards targeted therapeutic strategies for these disorders.
  • To underscore the potential for reducing unmet therapeutic needs in leukodystrophy patients.

Main Methods:

  • Review of recent advancements in diagnostic technologies for inherited neurological disorders.
  • Analysis of emerging therapeutic approaches for specific leukodystrophies.
  • Evaluation of the current landscape of treatment strategies and clinical trials.

Main Results:

  • Enhanced diagnostic capabilities have elucidated the genetic and pathological underpinnings of many leukodystrophies.
  • Several leukodystrophies are progressing towards targeted therapeutic interventions.
  • A transition from symptomatic care to disease-specific treatments is becoming feasible.

Conclusions:

  • Improved diagnostics are pivotal in advancing leukodystrophy research and treatment.
  • Targeted therapies offer a promising future for managing these complex inherited disorders.
  • The field is moving towards addressing unmet needs through innovative therapeutic strategies.
Keywords:
Disease modifyingGene therapyGenomicsLeukodystrophyStem cellSymptomaticTherapy

More Related Videos

Mouse Models of Periventricular Leukomalacia06:24

Mouse Models of Periventricular Leukomalacia

Published on: May 18, 2010

30.6K
A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease07:17

A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease

Published on: January 29, 2021

6.9K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
388
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.8K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
821
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K